Blinding Sample Clauses

Blinding. Blinding shall be of the same materials as the hardcore be, crushed and graded from 4 mm upwards, free from clay, chemical or other pollution, pests, weed roots and rubbish.
AutoNDA by SimpleDocs
Blinding. ‌ Each study in the protocol is open label; no blinding to treatment assignment for individual subjects or their care-providers will be performed. However, aggregate study results will be blinded and tightly controlled until the end of each study.
Blinding. Blinding of selected laboratory results is available as an optional service from QLAB. If The Sponsor determines that there is a requirement for blinding of results in this clinical trial, such requirements will be defined in the Scope of Work.
Blinding. This is an open-label study.
Blinding. This study is single blind. The participant will be blinded to which study vaccine (MVA-NP+M1 or placebo) they are administered. The Investigator and all study staff acting to determine or record safety, as well as all laboratory staff will also remain blinded (“observer blind”). The pharmacist and any study staff administering the study vaccine will not be blinded. The volume and site of vaccination will be the same for both Group 1 and Group 2. Identical syringes and needles will be used for preparation and administration of each study vaccine. Study vaccine will be prepared out of sight of the participant.
Blinding. RCC analysts and other staff at the RCC were blinded to histology results, and pathologists were blinded to imaging results. RCC analysts were blinded to treatment assignment. Subject demographics, laboratory, anthropomorphic measurements, and medical history ACCEP XXX XXXXX CRIP T were collected at each clinical trial site. Statistical analyses were done with SAS (SAS Institute 2011, Base SAS 9·3 Procedures Guide) and Stata (StataCorp 2013, Stata Statistical Software: release 13). A single PDFF value was calculated for each MRI exam as the mean of the PDFF values for the nine anatomical liver segments. Demographic, histologic and imaging information were summarized with categorical variables expressed as numbers and percentages and continuous variables expressed by mean (± standard deviation [SD]). The proportion of subjects who had, vs did not have MRIs at baseline was compared with regard to treatment group, study site, demographics, liver enzymes, lipids, metabolic factors, co-morbidities, concomitant liver medications, and histology findings. Xxxxxxx partial correlation coefficients and 95% confidence intervals were estimated between PDFF and histologic variables (steatosis, lobular inflammation, hepatocellular ballooning, fibrosis, and portal inflammation) at baseline and for changes from baseline to 72 weeks. Diagnostic accuracy of PDFF to classify hepatic steatosis grade at baseline was tested for grades 0-1 vs 2-3, and grades 0-2 vs 3. Diagnostic accuracy of change in PDFF to classify change in hepatic steatosis grade from baseline to EOT was tested for: reduction vs no change/increase and increase vs no change/decrease. Cross-validated area under ROC (AUROC) curves using a jack-knife procedure and 95% CIs were estimated for each of these dichotomizations [26]. Cut-off PDFF values were estimated using the lowest threshold value for which there was ≥ 90% specificity to distinguish between these dichotomized categories. Sensitivity, positive predictive values (PPVs), and negative predictive valves (NPVs) were calculated along with 95% confidence intervals (CIs) fixing specificity at 90%. ACCEP XXX XXXXX CRIP T Of 283 adults enrolled in the FLINT trial from March 16, 2011 to December 3, 2012 at eight participating FLINT clinical trial sites, 113 (40%) had MRI and liver biopsy at baseline, 85 (30%) had MRI and liver biopsy at EOT, and 78 (28%) had MRI and liver biopsy at both time points. One subject with a baseline MRI but without a centrally-read ba...
BlindingThe formation surfaces on which concrete is to be placed shall be covered with either blinding concrete not less than 75mm thick, or waterproof, building paper, or polythene sheeting immediately after completion of the final trimming of the excavation.
AutoNDA by SimpleDocs
Blinding. Randomization to either Investigational or control device will only occur at the surgery visit (Visit 2) and therefore the subjects will be blinded to their randomly assigned treatment device prior to surgery and during the follow up period following surgery. While it is not possible to blind investigators and staff members to the treatment device used, Investigators and staff members will not learn of randomized device until immediately prior to use of device, so as to maintain subject blinding prior to the hernia repair. Investigators and staff members will be asked to maintain subject blinding through the course of the follow up visits so as to not bias subject feedback on applicable study assessments. No device assignment information will be included on the source documentation to be completed by the study subjects (e.g. pain and quality of life assessments) and staff members, including the Investigator(s), will be instructed to not disclose this information during each study visit. Subjects will receive the same standard of care prior to, during and following surgery regardless of randomized device assignment, and therefore will not be able to individually determine what device they have been randomized to. Randomization assignment will be revealed to subjects at conclusion of the study after all assessments and study visits are completed. A subject will be informed of their randomization assignment in the event they withdraw consent or are withdrawn from the study for any other reason.
Blinding. Study treatments will be administered in a double-blind fashion (i.e., subjects and site research staff will not know the treatment assigned, with the exception of the dispensing site pharmacist, central pharmacy, and designated TDNCC personnel. The following study procedures will be in place to ensure double-blind administration of test and control (IV gallium/placebo) study treatments: • Randomization assignments will be stored in a secure database and appropriately protected and backed up. • Access to the randomization code will be strictly controlled and limited to designated TDNCC study personnel. All other study personnel, investigators, and subjects will remain blinded to their study drug assignment throughout the study. • A volume and appearance-matched placebo will be utilized. • The site pharmacist will apply a blinded label to each one-liter bag of study drug. The study blind will be broken on completion of the clinical study and after the study database has been locked and study results released. The site investigators will be provided with each subject’s treatment assignment following completion of data analysis. During the study, the blind may be broken only in emergencies when knowledge of the subject’s treatment group is necessary for further patient management.
Blinding. This clinical trial is being conducted as a double-blind study; neither the investigator, supporting staff, nor the participant will be aware of the treatment the participant is receiving.
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!